High Extra-Tumoral $^{99m}$Tc-Macroaggregated Albumin Accumulation in a Fatty Liver in a Candidate for Transarterial Radioembolization Treatment

Vassiliki Lyra$^*$, Konstantinos Palialexis$^2$, Chrisostomos Constantos$^*$, Lazaros Reppas$^1$, Elias N Brountzos$^2$ and Sofia N Chatziloannou$^3$

Abstract

A patient with non-alcoholic fatty liver disease (NAFLD) and unresectable small-sized ($\leq$3 cm) diffuse liver metastases from adenocarcinoma of the rectosigmoid junction was assessed for treatment with transarterial radioembolization (SIRT). The right hepatic arteriogram demonstrated several hypervascular lesions. However, the planar and the SPECT images of the subsequent right hepatic arterial $^{99m}$Tc-MAA perfusion scintigraphy, revealed significantly heterogeneous distribution of $^{99m}$Tc-MAA particles and “hot spots”, not corresponding to lesion-specific sites.

The noncoincidence of the angiographic and the scintigraphic findings could be possibly influenced by hemodynamic changes, due to the presence of significant NAFLD. Because of the high risk-benefit ratio, the patient was considered to be an inappropriate candidate for SIRT.

Keywords

Transarterial radioembolization; SIRT; $^{90}$Y-microspheres; $^{99m}$Tc-MAA; Liver metastases; Liver tumor

Introduction

The local control of liver metastases represents the most reliable way to increase survival in metastatic ColoRectal Cancer (mCRC), since liver failure is responsible for the overwhelming majority of deaths, with surgery achieving the overall highest 5-year and 10-year survival for these patients [1]. Despite the latest expanded resectability criteria, based mainly on the future liver remnant [2], up to one fourth of patients with mCRC are diagnosed with liver metastases at presentation, the majority of which has unresectable disease [3,4]. The local control of unresectable disease by liver-directed ablation and embolization therapies, such as Selective Internal Radioembolization Treatment (SIRT) with $^{90}$Y-SIR-Spheres, has already demonstrated a positive clinical impact, as a salvage therapy [5,6]. Recent published data have achieved promising results in improving progression free-survival and extending resectability, when used in combination with systemic new multi-drug (cytotoxic and biological agents) therapy [7,8]. Large sample randomized trials are ongoing; in order to better determine the patient benefit [9], SIRT planning is based on hepatic arterial perfusion scintigraphy, which implicates the selective administration of $^{99m}$Tc-Macro-Aggregated Albumin ($^{99m}$Tc-MAA) into the common hepatic artery or its branches, during the angiography procedure. The lung shunt fraction (LSF) [10,11] and the tumoral to non-tumoral $^{99m}$Tc-MAA accumulation tissue ratio (TNR) [11-13] is assessed on the acquired planar and SPECT images. Patients with high LSF and/or low TNR should be excluded from radioembolization treatment, due to increased risk of radiation induced lung and/or hepatic injury [13,14].

We describe a case of SIRT planning assessment in a fatty liver with multiple small liver metastases from rectal cancer. An unexpectedly high $^{99m}$Tc-MAA distribution in the non-tumoral liver tissue was achieved.

Case

A 73-year’s old man, in a well-preserved performance status, a former smoker with a normal weight and no history of alcohol consumption, experienced the worsening of a long onset rectorrhagia. His medical history resulted a long-standing diagnosis of familiar hypertriglyceridermia and diabetes mellitus type 2. He had a surgical treatment for prostate and laryngeal cancer about six and four years ago, respectively, and since then he was free of disease. The endoscopic examination of the large bowel, performed to investigate the enterorrhagia revealed a high rectal mass. The specimen biopsy showed a moderately differentiated adenocarcinoma. Imaging procedures, such as fluorine-18-fluorodeoxyglucose positron emission tomography /computed tomography ($^{18F}$FDG-PET/CT), demonstrated a T3N0M1 rectal cancer with multiple small-sized (<3 cm) liver limited metastases (Figure 1). A low anterior resection of the primary rectal cancer was immediately undertaken, due to the rectal bleeding, and the low rectal tumor burden which required no extensive surgical excision. Five weeks following surgery, the patient received four cycles of XELOX and four cycles of FOLFOXIRI/Panitumumab, as first-line and second-line chemotherapy treatment, respectively. The multidrug therapy had no impact on the resectability conversion of the metastatic disease but at least, a stable disease was achieved.

At this point, the application of a liver-directed therapy was assessed as a salvage treatment. Due to the several, in various depths, small-sized liver lesions, radioembolization treatment with $^{90}$Y-SIR-spheres was considered. However, patient had an increased hepatotoxic risk due to the presence of significant steatosis (Non-Alcoholic Fatty Liver Disease, NAFLD), revealed by the staging computed tomography scan (CT). As it is well known, the presence of a fatty-appearing liver on unenhanced CT scan (Figure 2), indicates a significant NAFLD and the most common pattern is the more or less irregular “diffuse” fat deposition, in accordance to the regional portal flow, with or without “. All liver biochemistry tests were normal and thus, five months after the primary tumor resection, patient underwent a SIRT planning angiography procedure, during which the selective right (Figure 3) and left hepatic arteriogram clearly revealed the presence of neoangiogenetic lesions.
The “staged” approach (distinct radioembolization treatment for each hepatic lobe within a 30-day interval) [5,11], was considered safer than the “whole” liver approach. Thus, after a prophylactic coil embolization of all visible extrahepatic vessels originating from the hepatic vasculature (Figure 3), 148MBq of ⁹⁹mTc-MAA, approximately 200,000 particles of an average diameter of 35 μm (MAASOL, GE Healthcare), were administered by catheter position into the right hepatic artery. ⁹⁹mTc-MAA scintigraphy data were acquired approximately half an hour after injection at the department of nuclear medicine, by a single-head GE Millenium gamma camera, with a LEHR collimator and an energy window set at 140keV ± 15%. No extrahepatic distribution of ⁹⁹mTc-MAA was revealed on the whole-body planar images (Figure 4) and the calculated LSF was 2.2%. However, a significantly disomogeneous ⁹⁹mTc-MAA distribution in

---

Figure 1: Patient's ¹⁸F-FDG-PET/CT staging scan.

Note: Increased ¹⁸F-FDG uptake by the primary rectal cancer (SUVmax=15) (intersection lines, figure 1a) and two of the small metastases of the right hepatic lobe, at the segment VIII (SUVmax=5.1) and the segment IVA (SUVmax=3.6) (arrow and intersection lines, figure 1b) are demonstrated.

Figure 2: Patient’s unenhanced CT staging scan.

Note: The attenuation criteria for the diagnosis of significant steatosis are largely satisfied (Figure 2a). Moreover, due to the significant low liver attenuation, the hepatic vasculature (arrow), and some of the metastases (arrowhead), appear hyperattenuated (Figure 2b).
the right lobe, with elevated and faint activity areas and some "hot spots", mimicking the presence of underlying metastatic disease were most evident (Figure 4). Abdominal SPECT imaging (64 views of 20 sec each, stored in a 128×128 matrix, for a 360°orbit) confirmed the absence of 99mTc-MAA delivery outside the liver and its highly irregular distribution in the hepatic lobe parenchyma (Figure 5). Cross-sectional evaluation of SPECT with CT data did not reveal any specific radiotracer accumulation that could be attributed to the liver metastases.

Consequently, the unfavorable ratio between the predicted effectiveness of radioembolization treatment (responsiveness of metastatic disease) and the risk of Radioembolization Induced Liver Disease (REILD), led to the postponement of patient’s 90Y-SIR-Spheres administration for more suitable contingent.

Discussion
NAFLD is the most common cause of hepatic steatosis (20% of patients planned for hepatectomy) [17] and may be considered as the hepatic component of the metabolic syndrome [18]. Patient’s fasting serum triglycerides were always elevated, even over 1000 mg/dl, although they were controlled much better in the past few years. Familiar hypertriglyceridemia (three of our patient’s brothers also had hypertriglyceridemia), is a common autosomal dominant disorder, whose genetic and biochemical base is not yet understood. It often coexists with hyperglycemia, which acts aggravating to serum triglycerides levels [18].

Patients with NAFLD are considered more susceptible to chemotherapy-induced liver injury, and progression to Non-Alcoholic Steato-Hepatitis (NASH), due to the background of increased hepatocellular oxidative stress [19]. Moreover, fluorouracil, irinotecan and oxaliplatin which were included in the patient’s chemotherapeutic regimen, have been specifically associated with increased risk of steatosis, steatohepatitis and sinusoidal obstruction syndrome, respectively [20,21].

The delivery of 99mTc-MAA particles to metastatic disease during the hepatic intra-arterial perfusion scintigraphy for SIRT planning, is considered in general, although with some limitations [22], comparable to that of 90Y-SIR-spheres and predictive of lesion responsiveness to the internal radiation [10,23]. However, despite the comparable hemodynamic performance, the 99mTc-MAA particles (greater variability of size and, consequently, of a specific activity), usually exaggerate [23,24] the flow differences between liver metastases as well as between them and normal tissue, compared to SIRT-microspheres (relative stable size and amount of radioactivity per sphere). Moreover, the high number of 99mTc-MAA particles injected (100-200 times more) compared to that of 99mTc-MAA particles, present an embolizing effect during their slow intra-arterial somministration, which probably change the flow profile and delivers the latter portion of microspheres to relatively hypovascular tumors [24]. Additionally, it should be noticed that the less selective (main hepatic artery compared to segmental branches), the intra-arterial somministration of 90Y-microspheres or 90Y-Tc-MAA particles (e.g. in case of diffuse metastatic disease, as patient’s case) is, the higher will be the inhomogeneity of particle distribution to tumoral and normal liver parenchyma will be. The microspheres enter predominantly into the larger vessels with higher blood flow due to their axial flow (wall exclusion effect) [24]. The asymmetric branching generates inhomogeneity, since the larger microspheres will preferentially follow the main vessel and be progressively separated from the smaller ones. Consequently, a faint inhomogeneous activity of the normal liver tissue in planar 99mTc-MAA scintigraphy is common, just as common is the occasionally appearance of "hot spots", due to the increased radiotracer accumulation in otherwise normal liver areas [24]. So, in case of the unavailability of a hybrid system, the acquisition of SPECT data and their comparative evaluation with morphological CT data, either by using or not using any fusion techniques, are useful to avoid misinterpretations [23,24], as in our patient’s case. This “structured heterogeneity” of particles’ delivery, which was recently confirmed at a microscopic level [25], is considered important for the “liver-sparing” effect on dose distribution [26].

Significant hemodynamics changes occur early in NASH, as it was recently demonstrated by xenon CT [27] and a contrast Ultrasonography Doppler scan [28]. The blood flow to the low resistance/low pressure portal vein system (Portal Vein Total Blood Flow, PVTBF), was less in NASH (even in simple steatosis) at an earlier stage, compared to chronic Hepatitis-C [27]. This is due to
the impairment of fatty liver microcirculation, which is not only correlated to the degree of perisinusoidal fibrosis but also to that of hepatocellular fat infiltration, which compresses the sinusoidal networks [29]. On the other hand, (Hepatic Total Blood Flow, HTBF) is relatively maintained despite the steatosis and the fibrosis, by increasing HATBF (Hepatic Arterial Total Blood Flow), due to the compensatory mechanism of the "Hepatic Arterial Buffer Response", designed for HTBF preservation. HTBF is most important, not only for the metabolic needs of the liver but also for the homeostatic needs of the entire body [30].

It still remains unclear which individuals with moderate to severe NAFLD, are at greater risk for progression (10-20% of cases) to inflammatory NASH, although it is probable that the more severe the steatosis and the risk factors are, like diabetes, the more likely it becomes to be complicated by steatohepatitis (NASH) [31]. The available imaging techniques cannot differentiate steatohepatitis from steatosis, since they are unreliable in diagnosing mild degrees of fibrosis [29]. There is also a poor correlation between biochemical and histological findings (silent NASH), since all spectrums of the histological NASH findings were found in patients with normal liver biochemistry [31].

In summary, the patient’s imaging was conformed to multiple small metastases of <3 cm and a severe fatty infiltration of the liver. Only, a liver biopsy, which was not performed, could have had address the compresence of steatohepatitis and the genomic characteristics (e.g. K-RAS status) of liver metastases as well. The subsequent hepatic arteriogram did not reveal any liver vascularization problems and brought out multiple small hypervascularized lesions. Conversely, the $^{99m}$Tc-MAA-intra-arterial scintigraphy demonstrated a significant heterogeneous irrigation into the different segments without any apparent accumulation at the lesions. According to previous considerations, the heterogeneous distribution of $^{99m}$Tc-MAA particles could possibly be enchanced by the underlying HATBF changes, characterizing NAFLD or NASH. It should be noticed that the majority of patient’s small-sized lesions were not affected by limit resolution and partial volume effect of SPECT imaging, and they would be clearly distinguishable in case of a more favourable distribution of the background activity. Moreover, despite some data in apparent conflict about the tumor size and the TNR [12], the most pronounced arterialization is actually found in the rim of metastases >1.5 cm, followed by that of metastases <1.5 cm, and finally by the central area of larger metastases [25]. So, the patient’s blood flow in preferential arterial hepatic ways resulted in marked radiotracer activity differences through hepatic parenchyma and prevented the emergence of the small-sized metastases and that of a favourable TNR (tumoral to non-tumoral tissue ratio).

At this point, the patient SIRT planning re-assessment, following the intra-arterial administration of angiotensin II (ATII) was evaluated, in order to re-distribute arterial blood flow from non-tumoral to tumoral areas. Recently available data [32] demonstrated a significant improvement of the arterial blood supply of liver metastases using ATII (up to ten times for the smaller ones, using intra-operative Doppler flowmetry), due to the lack of its vasoconstrictor effect on immature tumor vessels. However, the uncertainty of the baseline perfusion, even for the larger lesions, discouraged a new attempt of SIRT planning assessment under pharmacological intervention.

**Conclusion**

During SIRT planning for diffuse small-sized metastatic disease therapy, the background of severe NAFLD could address a low TNR and a highly heterogeneous distribution of $^{99m}$Tc-MAA particles, due to microcirculation flow modifications. These findings increase the risk of REILD obviating radioembolization treatment with $^{90}$Y-microspheres.

**References**


doi: 10.4172/2324-9110.1000180


Author Affiliations

1Department of Radiology, Nuclear Medicine Section, National and Kapodistrian University of Athens, Attikon Hospital, 1 Rimini St., Athens 12462, Greece

2Department of Radiology, Interventional Radiology Unit, National and Kapodistrian University of Athens, Attikon Hospital, 1 Rimini St., Athens 12462, Greece

Submit your next manuscript and get advantages of SciTechnol submissions

- 80 Journals
- 21 Day rapid review process
- 3000 Editorial team
- 5 Million readers
- More than 5000 TechNotes
- Quality and quick review processing through Editorial Manager System

Submit your next manuscript at www.scitechnol.com/submission